137 related articles for article (PubMed ID: 8849653)
1. Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
Barchiesi F; Hollis RJ; Messer SA; Scalise G; Rinaldi MG; Pfaller MA
Diagn Microbiol Infect Dis; 1995 Nov; 23(3):99-103. PubMed ID: 8849653
[TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
Franzot SP; Hamdan JS
Antimicrob Agents Chemother; 1996 Mar; 40(3):822-4. PubMed ID: 8851624
[TBL] [Abstract][Full Text] [Related]
4. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ;
FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
[TBL] [Abstract][Full Text] [Related]
5. Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela.
Calvo BM; Colombo AL; Fischman O; Santiago A; Thompson L; Lazera M; Telles F; Fukushima K; Nishimura K; Tanaka R; Myiajy M; Moretti-Branchini ML
J Clin Microbiol; 2001 Jun; 39(6):2348-50. PubMed ID: 11376089
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
Li M; Liao Y; Chen M; Pan W; Weng L
Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group.
Brandt ME; Pfaller MA; Hajjeh RA; Graviss EA; Rees J; Spitzer ED; Pinner RW; Mayer LW
J Infect Dis; 1996 Oct; 174(4):812-20. PubMed ID: 8843221
[TBL] [Abstract][Full Text] [Related]
8. Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates.
Del Poeta M; Barchiesi F; Arzeni D; Marinucci G; Scalise G
Mycoses; 1994; 37(11-12):411-6. PubMed ID: 7659128
[TBL] [Abstract][Full Text] [Related]
9. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
10. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
12. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.
Poonwan N; Mikami Y; Poosuwan S; Boon-Long J; Mekha N; Kusum M; Yazawa K; Tanaka R; Nishimura K; Konyama K
Eur J Epidemiol; 1997 Apr; 13(3):335-40. PubMed ID: 9258534
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
14. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
[TBL] [Abstract][Full Text] [Related]
15. Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas.
Delgado AC; Taguchi H; Mikami Y; Myiajy M; Villares MC; Moretti ML
Mycopathologia; 2005 Jan; 159(1):7-11. PubMed ID: 15750727
[TBL] [Abstract][Full Text] [Related]
16. Genotypic diversity and antifungal susceptibility of Cryptococcus neoformans isolates from paediatric patients in China.
Hong N; Chen M; Xu N; Al-Hatmi AMS; Zhang C; Pan WH; Hagen F; Boekhout T; Xu J; Zou XB; Liao WQ
Mycoses; 2019 Feb; 62(2):171-180. PubMed ID: 30341799
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients.
Jessup CJ; Pfaller MA; Messer SA; Zhang J; Tumberland M; Mbidde EK; Ghannoum MA
J Clin Microbiol; 1998 Oct; 36(10):2874-6. PubMed ID: 9738036
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility testing of Cryptococcus neoformans: a microdilution technique.
Ghannoum MA; Ibrahim AS; Fu Y; Shafiq MC; Edwards JE; Criddle RS
J Clin Microbiol; 1992 Nov; 30(11):2881-6. PubMed ID: 1452658
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
